Drug Efficacy - AstraZeneca's experimental hypertension pill demonstrated a blood pressure reduction more than twice that of standard treatment in a large late-stage study [1] Competitive Landscape - The study results enhance AstraZeneca's prospects for competing in a crowded hypertension treatment market [1]